Fractyl Health Gains Dutch Nod for Phase 1/2 RJVA-001 Gene Therapy Trial
GUTS•Fractyl Health won Dutch approval to launch a Phase 1/2 AAV-based gene therapy trial of RJVA-001 for type 2 diabetes, with patient dosing and preliminary data due in late 2026. The study is funded through early 2027 from existing cash runway, with no change to Fractyl’s capital plans.
1. Dutch Approval Grants Trial Go-Ahead
Fractyl Health received Clinical Trial Application authorization in the Netherlands to initiate a Phase 1/2 first-in-human study of RJVA-001, marking the first AAV-based gene therapy candidate for type 2 diabetes to enter clinical development.
2. Study Design and Timelines
The open-label trial features three single-ascending-dose cohorts followed by an optional expansion of up to 20 participants, using endoscopic ultrasound-guided intrapancreatic infusion, with first patient dosing and preliminary safety and efficacy data expected in late 2026.
3. Financial Strategy and Pipeline Impact
Development of RJVA-001 is fully funded within the existing cash runway into early 2027 with no changes to capital plans, positioning Fractyl as a dual clinical-stage company alongside its Revita pivotal program for post-GLP-1 weight maintenance.
